Venous thromboembolism and nonsmall cell lung cancer: A pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials

Cancer

Volumn 115, Issue 23, 2009, Pages 5516-5525

  Hicks, Lisa K ^a,b   Cheung, Matthew C ^b,c   Ding, Keyue ^d   Hasan, Baktiar ^d   Seymour, Lesley ^d   Le Maître, Aurélie ^d   Leighl, Natasha B ^b,e   Shepherd, Frances A ^b,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d Queen's Cancer Research Institute   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Adjuvant chemotherapy; Antineoplastic combined chemotherapy protocols; Complications; Drug therapy; Epidemiology; Etiology; Lung neoplasms; Mortality; Venous thromboembolism

Indexed keywords

CARBOPLATIN; CISPLATIN; ERLOTINIB; NAVELBINE; PACLITAXEL; REBIMASTAT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANADA; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY CANCER; FEMALE; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBESITY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FORECASTING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OBESITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VENOUS THROMBOEMBOLISM;

EID: 72249085780     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24596     Document Type: Article

References (37)

1. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population- based case-control study. Arch Intern Med. 2000;160: 809-815. (Pubitemid 30165241)
2. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78: 285-291.
3. Rickles FR, Levine M, Edwards RL. Haemostatic alterations in cancer patients. Cancer Metastasis Rev. 1992;11: 237-248.
4. Maiolo A, Tua A, Grignani G. Hemostasis and cancer: tumour cells induce the expression of tissue factor-like procoagulant activity on endothelial cells. Haematologica. 2002; 87: 624-628. (Pubitemid 34640645)
5. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9:286-294.
6. Clahsen PC, van de Velde CJ, Julien JP, et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994;12:1266-1271.
7. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404-407. (Pubitemid 18044179)
8. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98: 1614-1615.
9. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-831. (Pubitemid 43363369)
10. Rus C, Bazzan M, Palumbo A, et al. Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. J Thromb Haemost. 2004;2:2063-2065. (Pubitemid 40192769)
11. Chew HK, Davies AM, Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008;6:601-608.
12. Khorana AA, Francis CW, Culakova E, et al. Risk factors for venous thromboembolism in a prospective observational study. Cancer. 2005;104:2822-2829.
13. Behrendt CE, Ruiz RB. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost. 2003;90:734-737.
14. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin versus observation in resected nonsmall- cell lung cancer. N Engl J Med. 2005;352:2589-2597. (Pubitemid 41007845)
15. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS- 275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol. 2005;23:2831-2839. (Pubitemid 46179474)
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132. (Pubitemid 41058344)
17. Heit JA. Risk factors for venous thromboembolism. Clin Chest Med. 2003;24:1-12.
18. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89:493-498. (Pubitemid 36329240)
19. Pomp ER, le Cessie S, Rosendaal FR, et al. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol. 2007;139:289-296.
20. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084. (Pubitemid 44749316)
21. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098. (Pubitemid 44749317)
22. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in nonsmall- cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027-1032. (Pubitemid 46596751)
23. Elice F, Jacoub J, Rickles FR, et al. Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol. 2008;83:862-870.
24. Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 2002;20:1657-1667. (Pubitemid 34260548)
25. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277-2285.
26. Kuderer NM, Francis CW, Culakova E, et al. Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy [abstract]. J Clin Oncol.2008;26(15 suppl):507s. Abstract 9521.
27. Hicks LK, Selby R. Recent advances in the epidemiology, pathophysiology, and management of thrombosis in cancer patients. Lab Med. 2004;35:492-496. (Pubitemid 38971739)
28. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest.2003;124:58S-68S.
29. Versteeg HH, Peppelenbosch MP, Spek CA. Tissue factor signal transduction in angiogenesis. Carcinogenesis. 2003;24:1009-1013.
30. Beer JH, Haeberli A, Vogt A, et al. Coagulation markers predict survival in cancer patients. Thromb Haemost. 2002;88:745-749. (Pubitemid 35345330)
31. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer. 2003;97:3044-3052. (Pubitemid 36676259)
32. Grau JJ, Font C, Visa L, et al. Cancer and venous thromboembolism: role of genetic polymorphisms in selectins and tissue factor [abstract]. J Clin Oncol.2008;26(15 suppl): 503s. Abstract 9504.
33. Haas SK, Kakkar AK, Kemkes-Matthes B, et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies [abstract]. J Thromb Haemost. 2005;3(suppl 1). Abstract OR059.
34. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490-5505. (Pubitemid 350232226)
35. Khorana AA. The NCCN clinical practice guidelines on venous thromboembolic disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist. 2007;12:1361-1370.
36. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24:484-490. (Pubitemid 46630468)
37. Khorana AA, Kuderer NM, Kulakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111: 4902-4907.